New York, Jan 19, 2026, 16:33 EST — Markets have closed for the day.
- U.S. markets are closed today for Martin Luther King Jr. Day, shortening the trading week ahead.
- Abbott will release its fourth-quarter results on Jan. 22, with the company’s guidance expected to shape the next move.
- Traders are reacting to an FDA notice related to specific FreeStyle Libre 3 sensors.
Abbott Laboratories shares are inactive Monday as Wall Street shuts down for the Martin Luther King Jr. Day holiday, cutting the trading window before the company’s upcoming earnings release. AP News
Abbott’s update is key as investors seek clarity on what “steady” growth means for major healthcare players. It’s the guidance, more than the quarterly results, that usually drives the stock’s direction.
Abbott dropped in Friday’s final session, mirroring a slightly softer market and tracking closely with other major healthcare stocks. MarketWatch
The stock ended the day at $121.76, slipping 1.43%, after moving between $121.54 and $123.49. Trading volume hit roughly 10.4 million shares. Its 52-week range remains between $113.50 and $141.23. Investing.com
The company raised its quarterly dividend to 63 cents per share, payable on Feb. 13 to shareholders recorded by Jan. 15 — the date after which the stock begins trading ex-dividend. Abbott MediaRoom
Abbott plans to release its fourth-quarter 2025 results on Thursday, Jan. 22, ahead of the market open. The company will hold a webcast of the earnings call at 8 a.m. Central (9 a.m. Eastern). Abbott MediaRoom
Analysts monitored by Zacks forecast Abbott’s quarterly earnings around $1.50 per share, with revenue near $11.79 billion, according to a Zacks report cited by Finviz. Finviz
Abbott is ramping up its Libre diabetes ecosystem, unveiling a new Libre Assist feature within its app designed to guide users in making food choices on the spot. “People living with diabetes need more than apps that just log food and fall short of helping them with meal decisions,” said Marc Taub, vice president of Abbott’s diabetes care division, in a company statement. Abbott MediaRoom
Near-term risk this week centers on Abbott’s FreeStyle Libre 3 sensor. The company announced a medical device correction for certain Libre 3 and Libre 3 Plus sensors in the U.S. after internal tests revealed some units could register falsely low glucose levels. Abbott said it has fixed the manufacturing problem and does not anticipate major supply issues. The company also reported 736 severe adverse event cases worldwide, including seven deaths possibly linked to the problem, though none of the fatalities occurred in the U.S. U.S. Food and Drug Administration
Certain FreeStyle Libre 3 Plus sensors have been placed under a Class I device recall, the FDA’s highest warning level, signaling a reasonable chance that their use might lead to serious injury or death. FDA Access Data
Investors will focus on one key, complicated thing next: if Abbott signals any financial impact from replacements, plus whether demand for its diabetes-care and wider medical device products stays strong into 2026. Changes in how the company talks about the Libre system or new regulatory news could stir the pot.
Trading picks up again Tuesday. The next major event is the earnings release and conference call scheduled for Thursday, Jan. 22.
